AbbVie (ABBV) announced that it has completed its acquisition of Cerevel Therapeutics (CERE). With the completion of the acquisition, Cerevel is now part of AbbVie. AbbVie has acquired all outstanding Cerevel common stock for $45.00 per share. It is expected that Cerevel’s common stock will cease to trade on the NASDAQ stock exchange prior to market open on August 1. This acquisition is expected to be accretive to adjusted diluted earnings per share beginning in 2030.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie Completes Acquisition of Cerevel Therapeutics
- AbbVie price target raised to $210 from $195 at Truist
- AbbVie announces European Commission approval of Skyrizi
- AbbVie price target raised to $200 from $187 at Barclays
- ABBV Earnings: AbbVie Exceeds Q2 Expectations Driven by Strong Immunology Sales
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue